See more : Hang Yick Holdings Company Limited (1894.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Calithera Biosciences, Inc. (CALA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Calithera Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Tesla, Inc. (TSLA) Income Statement Analysis – Financial Results
- Securitag Assembly Group Co., Ltd. (6417.TWO) Income Statement Analysis – Financial Results
- Keon Capital Inc. (PSRVF) Income Statement Analysis – Financial Results
- Middle East Specialized Cables Company (2370.SR) Income Statement Analysis – Financial Results
- Arbor Realty Trust, Inc. (ABR) Income Statement Analysis – Financial Results
Calithera Biosciences, Inc. (CALA)
About Calithera Biosciences, Inc.
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 9.75M | 0.00 | 0.00 | 22.25M | 25.96M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.39M | 1.43M | 1.87M | 1.85M | 0.00 | 0.00 | 297.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.39M | 8.32M | -1.87M | -1.85M | 22.25M | 25.96M | -297.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 85.29% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 28.53M | 53.46M | 71.02M | 76.29M | 66.20M | 43.11M | 27.75M | 23.75M | 16.37M | 9.90M | 6.56M |
| General & Administrative | 13.54M | 20.85M | 20.37M | 16.61M | 13.34M | 12.53M | 10.59M | 9.07M | 5.35M | 2.48M | 1.42M |
| Selling & Marketing | -1.39M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 12.16M | 20.85M | 20.37M | 16.61M | 13.34M | 12.53M | 10.59M | 9.07M | 5.35M | 2.48M | 1.42M |
| Other Expenses | 0.00 | 50.88M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.00K | 1.00K | 0.00 |
| Operating Expenses | 40.69M | 74.31M | 91.39M | 92.90M | 79.54M | 55.64M | 38.33M | 32.82M | 21.72M | 12.38M | 7.98M |
| Cost & Expenses | 42.07M | 74.31M | 91.39M | 92.90M | 79.54M | 55.64M | 38.33M | 32.82M | 21.72M | 12.38M | 7.98M |
| Interest Income | 0.00 | 345.00K | 1.25M | 3.04M | 2.65M | 1.86M | 330.00K | 175.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.39M | 1.43M | 1.87M | 1.85M | 505.00K | 365.00K | 297.00K | 404.00K | 361.00K | 281.00K | 269.00K |
| EBITDA | -38.27M | -115.43M | -88.27M | -88.02M | -57.28M | -29.69M | -37.71M | -32.24M | -21.35M | -12.10M | -4.82M |
| EBITDA Ratio | 0.00% | -140.34% | 0.00% | 0.00% | -257.40% | -114.37% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -42.07M | -115.43M | -91.39M | -92.90M | -57.28M | -29.69M | -38.33M | -32.82M | -21.72M | -12.38M | -7.98M |
| Operating Income Ratio | 0.00% | -1,183.93% | 0.00% | 0.00% | -257.40% | -114.37% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.42M | 345.00K | 1.25M | 3.04M | 2.65M | 1.86M | 330.00K | 175.00K | 9.00K | 1.00K | 0.00 |
| Income Before Tax | -39.65M | -115.09M | -90.14M | -89.86M | -54.63M | -27.83M | -38.00M | -32.64M | -21.71M | -12.38M | -7.98M |
| Income Before Tax Ratio | 0.00% | -1,180.39% | 0.00% | 0.00% | -245.48% | -107.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -20.78M | 50.25M | -1.61M | -3.51M | -3.16M | -365.00K | -297.00K | -404.00K | -361.00K | 0.00 | 0.00 |
| Net Income | -18.87M | -165.34M | -88.52M | -86.35M | -51.47M | -27.83M | -38.00M | -32.64M | -21.71M | -12.38M | -7.98M |
| Net Income Ratio | 0.00% | -1,695.77% | 0.00% | 0.00% | -231.29% | -107.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -7.94 | -44.77 | -25.73 | -36.50 | -28.12 | -16.89 | -39.01 | -36.18 | -93.34 | -31.36 | -20.21 |
| EPS Diluted | -7.94 | -44.77 | -25.73 | -36.50 | -28.12 | -16.89 | -39.01 | -36.18 | -93.34 | -31.36 | -20.21 |
| Weighted Avg Shares Out | 4.99M | 3.69M | 3.44M | 2.37M | 1.83M | 1.65M | 974.30K | 902.25K | 232.60K | 394.69K | 394.69K |
| Weighted Avg Shares Out (Dil) | 4.99M | 3.69M | 3.44M | 2.37M | 1.83M | 1.65M | 974.30K | 902.25K | 232.60K | 394.69K | 394.69K |
Calithera to Participate in Jefferies Virtual Healthcare Conference and SVB Leerink Oncology 1x1 Day
Calithera Biosciences Presents New Preclinical Data for CB-668 at Society for Immunotherapy of Cancer (SITC) 2020 Annual Meeting
Calithera Biosciences' (CALA) CEO Susan Molineaux on Q3 2020 Results - Earnings Call Transcript
Calithera Biosciences Reports Third Quarter 2020 Financial Results and Recent Highlights
Calithera Biosciences Announces Expansion of Ongoing Clinical Trial Evaluating Telaglenastat in Combination with palbociclib (IBRANCE®)
Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Calithera Biosciences Awarded up to $2.4M from Cystic Fibrosis Foundation to Support Clinical Development of Arginase Inhibitor, CB-280
Calithera Biosciences to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020
Yieldstreet Announces Financial Services Veteran John Siciliano as Chairman of the Yieldstreet Prism Fund Board
Source: https://incomestatements.info
Category: Stock Reports